Fibrotic scar after experimental autoimmune encephalomyelitis inhibits oligodendrocyte differentiation
Author(s) -
Stephanie L. Yahn,
Jiajun Li,
Irene Goo,
Han Gao,
Roberta Brambilla,
Jae K. Lee
Publication year - 2019
Publication title -
neurobiology of disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.205
H-Index - 166
eISSN - 1095-953X
pISSN - 0969-9961
DOI - 10.1016/j.nbd.2019.104674
Subject(s) - remyelination , experimental autoimmune encephalomyelitis , multiple sclerosis , extracellular matrix , encephalomyelitis , pathology , demyelinating disease , oligodendrocyte , progenitor cell , biology , immunology , neuroscience , medicine , myelin , stem cell , microbiology and biotechnology , central nervous system
Remyelination failure is a crucial component of disease progression in the autoimmune demyelinating disease Multiple Sclerosis (MS). The regenerative capacity of oligodendrocyte progenitor cells (OPCs) to replace myelinating oligodendrocytes is likely influenced by many aspects of the lesion environment including inflammatory signaling and extracellular matrix (ECM) deposition. These features of MS lesions are typically attributed to infiltrating leukocytes and reactive astrocytes. Here we demonstrate that fibroblasts also contribute to the inhibitory environment in the animal model of MS, experimental autoimmune encephalomyelitis (EAE). Using Col1α1 transgenic mice, we show that perivascular fibroblasts are activated in the spinal cord at EAE onset, and infiltrate the parenchyma by the peak of behavioral deficits where they are closely associated with areas of demyelination, myeloid cell accumulation, and ECM deposition. We further show that both fibroblast conditioned media and fibroblast ECM inhibit the differentiation of OPCs into mature oligodendrocytes. Taken together, our results indicate that the fibrotic scar is a major component of EAE pathology that leads to an inhibitory environment for remyelination, thus raising the possibility that anti-fibrotic mechanisms may serve as novel therapeutic targets for MS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom